{
    "clinical_study": {
        "@rank": "154801", 
        "acronym": "GELUPO", 
        "arm_group": [
            {
                "arm_group_label": "Glutamine", 
                "arm_group_type": "Experimental", 
                "description": "The patient group had 3x10 gr daily glutamine during first 4 cycles of mFOLFOX6 regimen."
            }, 
            {
                "arm_group_label": "Observation", 
                "arm_group_type": "No Intervention", 
                "description": "The group who had only mFOLFOX6 regimen, no additional intervention for neuropathy prophylaxis.."
            }
        ], 
        "brief_summary": {
            "textblock": "Oxaliplatin is a chemotherapeutic agent, which is generally used in treatment of colorectal\n      cancer. The dose limiting side effect of oxaliplatin is neurotoxicity. In this study we\n      aimed to determine whether glutamine has role in prevention of oxaliplatin induced\n      neuropathy."
        }, 
        "brief_title": "The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Peripheral Neuropathy", 
        "condition_browse": {
            "mesh_term": [
                "Peripheral Nervous System Diseases", 
                "Demyelinating Diseases", 
                "Polyneuropathies", 
                "Nerve Compression Syndromes", 
                "Neurologic Manifestations", 
                "Neurotoxicity Syndromes"
            ]
        }, 
        "detailed_description": {
            "textblock": "Our study population includes the colorectal cancer patient who is going to have mFOLFOX6\n      (modified, Folinic acid 400 mg/m2  1 day, oxaliplatin 85 mg/m2  1 day, 5-fluorouracil l 400\n      mg/m2 bolus 2400 mg/m2 continuous infusion 48 hours) regimen. We randomly assigned the\n      patients into two groups. We administered glutamine at dose of 3x10 gr/day to one patient\n      group concomitantly with mFOLFOX6 regimen and other group had no additional intervention.\n      We performed questionnaire, neurological examination and EMG (Electromyography) before and\n      after 4th cycle of  mFOLFOX6 regimen in both patient groups. We planned to compare the\n      neurological signs, symptoms and EMG action potentials between mFOLFOX6+Glutamine and only\n      mFOLFOX6 group. We aimed to search the role of glutamine as a prophylactic agent against\n      oxaliplatin induced neuropathy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age between 20 - 65 years\n\n          -  Operated and non operated colorectal cancer patients\n\n          -  Patient administering mFOLFOX 6 ( Folinic acid 400 mg/m2  1 day, oxaliplatin 85 mg/m2\n              1 day, 5-fluorouracil  400 mg/m2 bolus 2400 mg/m2 continuous infusion 48 hours)\n\n        Exclusion Criteria:\n\n          -  Patients who had chemotherapy in last 6 months\n\n          -  Diabetes Mellitus\n\n          -  Sensorimotor polyneuropathy\n\n          -  Anemia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02024191", 
            "org_study_id": "031"
        }, 
        "intervention": {
            "arm_group_label": "Glutamine", 
            "intervention_name": "Glutamine", 
            "intervention_type": "Dietary Supplement", 
            "other_name": "Resource Glutamine 3x10 gr per day"
        }, 
        "intervention_browse": {
            "mesh_term": "Oxaliplatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "glutamine", 
            "oxaliplatin", 
            "peripheral neuropathy"
        ], 
        "lastchanged_date": "December 30, 2013", 
        "location": {
            "contact": {
                "email": "drozanyazici@gmail.com", 
                "last_name": "Ozan Yazici, MD", 
                "phone": "+90 312 5084610"
            }, 
            "contact_backup": {
                "email": "nyozdemir@yahoo.com", 
                "last_name": "Nuriye Ozdemir, MD", 
                "phone": "+90 312 5084601"
            }, 
            "facility": {
                "address": {
                    "city": "Ankara", 
                    "country": "Turkey", 
                    "zip": "06230"
                }, 
                "name": "Ankara Numune Education and Research Hospital"
            }, 
            "investigator": {
                "last_name": "Ozan Yazici, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy in Colorectal Cancer Patients. Randomized Trial", 
        "overall_contact": {
            "email": "drozanyazici@gmail.com", 
            "last_name": "Ozan Yazici, MD", 
            "phone": "+90 312 5084610"
        }, 
        "overall_contact_backup": {
            "email": "nyozdemir@yahoo.com", 
            "last_name": "Nuriye Ozdemir, MD", 
            "phone": "+90 312 5084601"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Turkey: Ethics Committee", 
                "Turkey: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Electromyography action potential values will be compared between two patient groups.", 
            "measure": "Electromyography parameters", 
            "safety_issue": "No", 
            "time_frame": "4 months interval"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02024191"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ankara Education and Research Hospital", 
            "investigator_full_name": "Ozan Yazici", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Neurological signs and symptoms", 
            "safety_issue": "No", 
            "time_frame": "4 months"
        }, 
        "source": "Ankara Education and Research Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ankara Education and Research Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}